How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the ...

Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

CRISPR has some important elements in common with vaccine giant Moderna. And the company is heading for an important moment in its growth story. Today, CRISPR's market value sits at about $3.4 billion ...

“It’s a little scary, quite honestly,” says Dr. Jennifer Doudna, who helped develop CRISPR gene-editing technology. By David Marchese It’s entirely possible, maybe even likely, that during some slow ...

We expect CRISPR Therapeutics CRSP to surpass expectations when it reports second-quarter 2024 results next month. Let’s see how things have shaped up for the quarter to be reported. CRISPR ...